These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 7585059)

  • 1. Sickle cell paths converge on hydroxyurea.
    Platt OS
    Nat Med; 1995 Apr; 1(4):307-8. PubMed ID: 7585059
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
    Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
    [No Abstract]   [Full Text] [Related]  

  • 3. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiologically based drug treatment of sickle cell disease.
    Steinberg MH
    Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
    Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract]   [Full Text] [Related]  

  • 6. Seeking a way to alleviate sickle cell disease.
    Mitka M
    JAMA; 2002 Oct 23-30; 288(16):1970. PubMed ID: 12387636
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM; Ebert BL
    Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea for sickle cell anemia.
    Naina HV; Harris S
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA
    Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of hydroxyurea in sickle cell disease.
    Halsey C; Roberts IA
    Br J Haematol; 2003 Jan; 120(2):177-86. PubMed ID: 12542474
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydroxyurea and sickle cell disease: a chance for every patient.
    Weiner DL; Brugnara C
    JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739
    [No Abstract]   [Full Text] [Related]  

  • 12. Pathogenesis and treatment of sickle cell disease.
    Bunn HF
    N Engl J Med; 1997 Sep; 337(11):762-9. PubMed ID: 9287233
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term use of hydroxyurea for sickle cell anemia.
    Hagar W
    JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydroxycarbamide for sickle-cell anaemia in infancy.
    Weatherall DJ
    Lancet; 2011 May; 377(9778):1628-30. PubMed ID: 21571132
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
    Hoppe C; Vichinsky E; Quirolo K; van Warmerdam J; Allen K; Styles L
    J Pediatr Hematol Oncol; 2000; 22(4):330-4. PubMed ID: 10959903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemoglobin F modulation in childhood sickle cell disease.
    Trompeter S; Roberts I
    Br J Haematol; 2009 Feb; 144(3):308-16. PubMed ID: 19036119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biophysics of sickle cell hydroxyurea therapy.
    Eaton WA; Hofrichter J
    Science; 1995 May; 268(5214):1142-3. PubMed ID: 7539154
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacogenomics of hydroxyurea therapy and fetal hemoglobin levels in sickle cell anemia.
    Sales RR; Nogueira BL; Luizon MR
    Pharmacogenomics; 2022 May; 23(7):393-396. PubMed ID: 35546339
    [No Abstract]   [Full Text] [Related]  

  • 19. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: implications for pharmacological intervention.
    Marcus SJ; Ware RE
    J Pediatr Hematol Oncol; 1999; 21(5):407-11. PubMed ID: 10524455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.